Switch to RAL-containing regimen
Montreal Study : Switch ENF to RAL
Original article : J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):362-4 – A Talbot
Last update :
28/03/2014
Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK
- Pilot, open-label retrospective study
- 28 adults on salvage therapy with enfuvirtide-based regimen and HIV-1 RNA < 50 c/mL
- Switch of enfuvirtide to RAL 400 mg bid, the remainder of the salvage regimen being unchanged. At the time of the switch:
- ENF had been administered for a median of 25 months
- Salvage regimen: 1 PI/r, N = 27, 1 NNRTI, N = 6
- Follow-up of 6 months available for 27/28 patients
- 26 maintained HIV-1 RNA < 50 c/mL
- 1 single blip at 56 c/mL at W24
- No significant changes in the CD4 counts
- ENF-related injection site reactions resolved in all patients
- RAL was well tolerated
Back to Table of Contents
Download the slides
